Summary
Lupin Limited (Lupin) is transnational pharmaceutical company. It is one of the largest generic pharmaceutical companies across the world.The company focuses on the manufacture of generic and branded drugs, formulations and active pharmaceutical ingredients (API’s). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, GI, CNS, anti-infectives, NSAIDs, anti-TB and cephalosporins. The company undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. The company operates in India, the US, UK, Europe, Germany, Japan, South Africa, Philippines, and Australia. It operates subsidiaries in various countries across the world, some of which include Lupin Pharma Canada Limited; Lupin Pharmaceuticals Inc.; and Pharma Dynamics. Lupin is headquartered in Mumbai, Maharashtra, India.
Lupin Limited (LUPIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Lupin Limited, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Lupin Limited, Medical Devices Deals, 2010 to YTD 2016 12
Lupin Limited, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
Lupin Limited, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Lupin to Acquire Product Portfolio from Temmler Pharma 17
Glenmark Pharma Rumored To Sell Its Oral Contraceptives Division 18
Lupin Plans To Acquire US Branded Drugs 20
Lupin Acquires Worldwide Rights To Goanna Brand From Aspen Pharmacare 21
Private Equity 22
GlaxoSmithKline Withdraws Sale of Its Drugs 22
Partnerships 26
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 26
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 27
Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 28
Lupin Enters into Co-Development Agreement with Merck Serono 29
Lupin Enters into Distribution Agreement with Salix Pharma 30
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 31
Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 32
Gavis Pharma Partners with Modavar Pharma 33
Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 34
Lupin Plans Co-Marketing Agreement For Vaccines 35
Lupin Plans Marketing Agreement For Cardiovascular, Diabetes, Gynecology And Respiratory Drugs 36
Multicare Pharma Enters Into Co-Marketing Agreement With Sanofi 37
Eli Lilly and Company (India) Enters Into Co-Promotion Agreement With Lupin 39
Lupin Enters Into Joint Development Agreement With Medicis 40
Lupin Enters Into Co-Marketing Agreement With Natco Pharma 41
Innocore Technologies Enters Into Technology Integration Agreement With Nanomi 42
Licensing Agreements 43
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 43
Merck Enters Into Licensing Agreement With Lupin 44
Lupin Enters Into Licensing Agreement With NeuClone 46
Lupin Enters Into Patent Licensing Agreement With Abbott For Antara 47
Salix Pharma Extends Licensing Agreement With Lupin 48
Warner Chilcott Enters Into Licensing Agreement With Lupin For Femcon Fe 49
Warner Chilcott Enters Into Licensing Agreement With Lupin For Asacol 50
Salix Enters Into Licensing Agreement With Novel Labs For OsmoPrep 51
Salix Pharma And Norgine Enter Into Licensing Agreement With Novel Labs 52
Equity Offering 53
Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 53
Asset Transactions 54
G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 54
Lupin to Acquire Product Portfolio from Temmler Pharma 55
Perrigo Company Acquires Rights Of HalfLytely From Novel Labs 56
Acquisition 57
Lupin Acquires GAVIS Pharma for USD880 Million 57
Sagent Pharma May Sell Itself 59
Lupin May Acquire Sinclair IS Pharma for USD500 Million 61
Lupin Acquires Biocom 62
Lupin Acquires Medquimica 63
Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 64
Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 65
Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 67
Lupin Acquires Nanomi 68
Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 69
Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 70
Lupin Completes Acquisition Of I’rom Pharma 71
Lupin Holding Acquires Additional 7% Stake In Generic Health 73
Lupin Limited - Key Competitors 74
Key Employees 75
Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81
List of Tables
Lupin Limited, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Lupin Limited, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Lupin Limited, Deals By Therapy Area, 2010 to YTD 2016 10
Lupin Limited, Medical Devices Deals, 2010 to YTD 2016 12
Lupin Limited, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
Lupin to Acquire Product Portfolio from Temmler Pharma 17
Glenmark Pharma Rumored To Sell Its Oral Contraceptives Division 18
Lupin Plans To Acquire US Branded Drugs 20
Lupin Acquires Worldwide Rights To Goanna Brand From Aspen Pharmacare 21
GlaxoSmithKline Withdraws Sale of Its Drugs 22
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 26
Lupin and Boehringer Ingelheim Enters into Co-marketing Agreement 27
Lupin Enters into Development Agreement with Celon for Generic Advair Diskus 28
Lupin Enters into Co-Development Agreement with Merck Serono 29
Lupin Enters into Distribution Agreement with Salix Pharma 30
Lupin Enters into Distribution Agreement with LG Life Sciences for Insulin Analogue Glargine 31
Lupin Enters Into Joint Venture Agreement With Yoshindo To Form YL Biologics 32
Gavis Pharma Partners with Modavar Pharma 33
Lupin Enters Into Co-Promotion Agreement With Onset Dermatologics For Locoid Lotion 34
Lupin Plans Co-Marketing Agreement For Vaccines 35
Lupin Plans Marketing Agreement For Cardiovascular, Diabetes, Gynecology And Respiratory Drugs 36
Multicare Pharma Enters Into Co-Marketing Agreement With Sanofi 37
Eli Lilly and Company (India) Enters Into Co-Promotion Agreement With Lupin 39
Lupin Enters Into Joint Development Agreement With Medicis 40
Lupin Enters Into Co-Marketing Agreement With Natco Pharma 41
Innocore Technologies Enters Into Technology Integration Agreement With Nanomi 42
Romark Labs Enters Into Licensing Agreement With Lupin For Alinia 43
Merck Enters Into Licensing Agreement With Lupin 44
Lupin Enters Into Licensing Agreement With NeuClone 46
Lupin Enters Into Patent Licensing Agreement With Abbott For Antara 47
Salix Pharma Extends Licensing Agreement With Lupin 48
Warner Chilcott Enters Into Licensing Agreement With Lupin For Femcon Fe 49
Warner Chilcott Enters Into Licensing Agreement With Lupin For Asacol 50
Salix Enters Into Licensing Agreement With Novel Labs For OsmoPrep 51
Salix Pharma And Norgine Enter Into Licensing Agreement With Novel Labs 52
Lupin Plans to Raise USD1.2 Billion in Public Offering of Equity Securities 53
G&W Labs to Acquire Two Generic Drugs of Gavis Pharma from Lupin 54
Lupin to Acquire Product Portfolio from Temmler Pharma 55
Perrigo Company Acquires Rights Of HalfLytely From Novel Labs 56
Lupin Acquires GAVIS Pharma for USD880 Million 57
Sagent Pharma May Sell Itself 59
Lupin May Acquire Sinclair IS Pharma for USD500 Million 61
Lupin Acquires Biocom 62
Lupin Acquires Medquimica 63
Lupin to Acquire Remaining 40% Stake in Pharma Dynamics 64
Lupin Acquires Labs Grin, Ophthalmology Therapies Provider 65
Lupin Plans to Acquire Generics Manufacturing Companies In Europe for up to USD1 Billion 67
Lupin Acquires Nanomi 68
Gavis Pharma Revises Open Offer Price To Acquire Additional 26% Stake In Wintac For US$5 Million 69
Aenova Completes Acquisition Of Temmler Pharma, Contract Manufacturing Company 70
Lupin Completes Acquisition Of I’rom Pharma 71
Lupin Holding Acquires Additional 7% Stake In Generic Health 73
Lupin Limited, Key Competitors 74
Lupin Limited, Key Employees 75
Lupin Limited, Other Locations 77
Lupin Limited, Subsidiaries 78
List of Figures
Lupin Limited, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Lupin Limited, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Lupin Limited, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Lupin Limited, Medical Devices Deals, 2010 to YTD 2016 12
